Portal de Periódicos da CAPES

Datapoints: Use of Mood Stabilizers Among Patients With Schizophrenia, 1994-2001

2002; American Psychiatric Association; Volume: 53; Issue: 10 Linguagem: Inglês

10.1176/appi.ps.53.10.1212

1557-9700

Leslie Citrome, Ari Jaffe, Jerome Levine, Baerbel Allingham,

Child and Adolescent Psychosocial and Emotional Development

Back to table of contents Previous article Next article ColumnsFull AccessDatapoints: Use of Mood Stabilizers Among Patients With Schizophrenia, 1994-2001Leslie Citrome, M.D., M.P.H., Ari Jaffe, M.D., Jerome Levine, M.D., and Baerbel Allingham, M.S.Leslie Citrome, M.D., M.P.H., Ari Jaffe, M.D., Jerome Levine, M.D., and Baerbel Allingham, M.S.Published Online:8 Oct 2014https://doi.org/10.1176/appi.ps.53.10.1212AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail A previous study on the use of mood stabilizers and anticonvulsants among all patients with schizophrenia hospitalized in psychiatric centers operated by the New York State Office of Mental Health found an increase in use between 1994 and 1998 (1). Data were obtained retrospectively by querying a centralized database containing pharmacy prescription information. In the study reported here all inpatients with a DSM-IV diagnosis of schizophrenia who received at least one dose of any mood stabilizer during each calendar year from 1994 to 2001 were identified. Patients with schizoaffective disorder were not included.Use of these agents has increased (Figure 1). In 1994, 2,201 of 8,405 inpatients diagnosed as having schizophrenia (26.2 percent) received a mood stabilizer, with lithium the most commonly prescribed (1,109 patients, or 13.2 percent). In 2001, 1,950 of 4,139 (47.1 percent) received a mood stabilizer, with valproate the most commonly prescribed (1,445 patients, or 34.9 percent). In comparison, among patients hospitalized in 2001 with any diagnosis, 5,641 of 9,551 (59.1 percent) received a mood stabilizer.Some trends emerged between 1994 and 2001: use of valproate reached a plateau of 35 percent; lithium utilization decreased steadily, albeit at a slow rate; and use of carbamazepine decreased at a more rapid rate. Newer anticonvulsants were introduced. Gabapentin use peaked in 2000 and exceeded lithium use. Use of topiramate and oxcarbazepine now exceeds that of carbamazepine.Although the Expert Consensus Guidelines for the Treatment of Schizophrenia (2) recommend the use of lithium and anticonvulsants as adjunctive agents, little empirical evidence supports this recommendation.The data presented here are representative of a large state hospital system and may not be generalizable to other practice settings. Further issues related to interpreting these data are discussed elsewhere (1). Whether prescribing these agents for patients with schizophrenia is good or bad is impossible to answer without outcome data. Research is lagging behind clinical practice. The results reported here indicate an urgent need for controlled clinical trials to test the efficacy of the adjunctive use of mood stabilizers and anticonvulsants for patients with schizophrenia.AcknowledgmentsPartial support for the maintenance of the integrated research database is currently provided by a grant from Eli Lilly and Co. and in past years was provided by Eli Lilly and Co., the Janssen Research Foundation, and Pfizer, Inc.The authors are affiliated with the Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road Orangeburg, New York 10962 (e-mail, [email protected]). Harold A. Pincus, M.D., and Terri L. Tanielian, M.A., are editors of this column.Figure 1. Percentage of patients hospitalized in New York State psychiatric centers who received mood stabilizers, 1994 (N=8,405) through 2001 (N=4,139)References1. Citrome L, Levine J, Allingham B: Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services 51:634-638, 2000Link, Google Scholar2. McEvoy JP, Scheifler PL, Frances A: The Expert Consensus Guideline Series, Treatment of Schizophrenia. Journal of Clinical Psychiatry 60(suppl 11):43, 1999Google Scholar FiguresReferencesCited byDetailsCited BySpecific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to CariprazineHarvard Review of Psychiatry, Vol. 29, No. 1International Journal of Molecular Sciences, Vol. 19, No. 7Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illnessJournal of Affective Disorders, Vol. 188The Lancet, Vol. 384, No. 9949Asia-Pacific Psychiatry, Vol. 6, No. 2PLoS ONE, Vol. 9, No. 3Increasing use of atypical antipsychotics and anticonvulsants during pregnancy5 November 2012 | Pharmacoepidemiology and Drug Safety, Vol. 22, No. 7Clinical Psychopharmacology and Neuroscience, Vol. 10, No. 1Neuropsychiatry, Vol. 1, No. 4Reconnaître les symptômes psychiatriques iatrogènes liés aux antipsychotiquesL'Encéphale, Vol. 36, No. 5Prise en charge des états dangereux des pathologies mentales gravesSchizophrenia Research, Vol. 119, No. 1-3Psychiatric Quarterly, Vol. 80, No. 2Long-Term Use of Mood Stabilizers and Its Impact on the Quality of Life of Chinese Patients With SchizophreniaClinical Neuropharmacology, Vol. 32, No. 1Expert Review of Neurotherapeutics, Vol. 9, No. 1Valproate: do formulations matter?Journal of Clinical Pharmacy and Therapeutics, Vol. 33, No. 4Antiepileptics in the Treatment of Schizophrenia28 July 2010European Neuropsychopharmacology, Vol. 18, No. 3Neuropathology, Vol. 28, No. 2International Journal of Clinical Practice, Vol. 62, No. 8Psychotherapy and Psychosomatics, Vol. 77, No. 2CNS Drugs, Vol. 22, No. 1Modèle épigénétique chez la souris de la modulation pharmacologique de la vulnérabilité à la schizophrénieL'Encéphale, Vol. 33, No. 5Update: New Uses for Lithium and Anticonvulsants7 November 2014 | CNS Spectrums, Vol. 12, No. 11Pharmacokinetics of Aripiprazole and Concomitant CarbamazepineJournal of Clinical Psychopharmacology, Vol. 27, No. 3International Clinical Psychopharmacology, Vol. 22, No. 6Current Medical Research and Opinion, Vol. 23, No. 6Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE TrialMiranda H. Chakos, M.D.Ira D. Glick, M.D.Alexander L. Miller, M.D.Mark B. Hamner, M.D.Del D. Miller, M.D.Jayendra K. Patel, M.D.Andre Tapp, M.D.Richard S. E. Keefe, Ph.D.Robert A. Rosenheck, M.D.1 August 2006 | Psychiatric Services, Vol. 57, No. 8Incidence, Prevalence, and Surveillance for Diabetes in New York State Psychiatric Hospitals, 1997-2004Leslie Citrome, M.D., M.P.H.Ari Jaffe, M.D.Jerome Levine, M.D.David Martello1 August 2006 | Psychiatric Services, Vol. 57, No. 8Anticonvulsant Treatment for Psychiatric and Seizure Indications Among YouthsJulie Magno Zito, Ph.D.Daniel J. Safer, M.D.James F. Gardner, Sc.M.Karen Soeken, Ph.D.Jae Ryu, B.S.1 May 2006 | Psychiatric Services, Vol. 57, No. 5International Journal of Obesity, Vol. 30, No. 11Dosing of Second-Generation Antipsychotic Medication in a State Hospital SystemJournal of Clinical Psychopharmacology, Vol. 25, No. 4Drs. O'Donnell and Creamer ReplyMEAGHAN L. O'DONNELL, Ph.D., and MARK CREAMER, Ph.D., 1 March 2005 | American Journal of Psychiatry, Vol. 162, No. 3Monotherapy Versus Polypharmacy for Hospitalized Psychiatric PatientsLESLIE CITROME, M.D., M.P.H., ARI JAFFE, M.D., and JEROME LEVINE, M.D., 1 March 2005 | American Journal of Psychiatry, Vol. 162, No. 3Monotherapy Versus Polypharmacy for Hospitalized Psychiatric PatientsRAEL D. STROUS, M.D., and VLADIMIR LERNER, M.D., Ph.D., 1 March 2005 | American Journal of Psychiatry, Vol. 162, No. 3International Review of Psychiatry, Vol. 17, No. 1Toward Convergence in the Medication Treatment of Bipolar Disorder and SchizophreniaHarvard Review of Psychiatry, Vol. 13, No. 1The Journal of Clinical Pharmacology, Vol. 45, No. 1Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric InpatientsLeslie Citrome, M.D., M.P.H., Ari Jaffe, M.D., Jerome Levine, M.D., Baerbel Allingham, M.S., and James Robinson, M.Ed.1 September 2004 | Psychiatric Services, Vol. 55, No. 9Hargrave v. Vermont and the Quality of CareMichael Allen1 September 2004 | Psychiatric Services, Vol. 55, No. 9Hargrave v. Vermont and the Quality of CarePaul S. Appelbaum, M.D.1 September 2004 | Psychiatric Services, Vol. 55, No. 9Antihostility Effects of Adjunctive DivalproexRobert Eilers, M.D.1 September 2004 | Psychiatric Services, Vol. 55, No. 9Antihostility Effects of Adjunctive DivalproexLeslie Citrome, M.D., M.P.H.1 September 2004 | Psychiatric Services, Vol. 55, No. 9Positive Experiences With Giving Gifts to PatientsSue Matorin, M.S., A.C.S.W.1 September 2004 | Psychiatric Services, Vol. 55, No. 9A Study of the Safety, Efficacy, and Tolerability of Switching From the Standard Delayed Release Preparation of Divalproex Sodium to the Extended Release Formulation in Patients With SchizophreniaJournal of Clinical Psychopharmacology, Vol. 24, No. 3Adjunctive Divalproex and Hostility Among Patients With Schizophrenia Receiving Olanzapine or RisperidoneLeslie Citrome, M.D., M.P.H., Daniel E. Casey, M.D., David G. Daniel, M.D., Patricia Wozniak, Ph.D., Lisa D. Kochan, R.Ph., Ph.D., and Katherine A. Tracy, M.D., Ph.D.1 March 2004 | Psychiatric Services, Vol. 55, No. 3Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, No. 3 Volume 53Issue 10 October 2002Pages 1212-1212 Metrics PDF download History Published online 8 October 2014 Published in print 1 October 2002